BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16378908)

  • 1. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.
    Chinnaiyan P; Allen GW; Harari PM
    Semin Radiat Oncol; 2006 Jan; 16(1):59-64. PubMed ID: 16378908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy.
    Hendrickson AW; Haluska P
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1032-40. PubMed ID: 19777391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid cancer molecular signaling pathways and use of targeted therapy.
    Kundra P; Burman KD
    Endocrinol Metab Clin North Am; 2007 Sep; 36(3):839-53, viii. PubMed ID: 17673131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.
    Lackner MR
    Expert Rev Mol Diagn; 2010 Jan; 10(1):75-87. PubMed ID: 20014924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel small-molecule therapy of Hodgkin lymphoma.
    Buglio D; Georgakis G; Younes A
    Expert Rev Anticancer Ther; 2007 May; 7(5):735-40. PubMed ID: 17492936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein 90 as a drug target: some like it hot.
    Banerji U
    Clin Cancer Res; 2009 Jan; 15(1):9-14. PubMed ID: 19118027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in breast cancer: where are we now?
    Di Cosimo S; Baselga J
    Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
    Hartog H; Wesseling J; Boezen HM; van der Graaf WT
    Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Newton HB
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
    Martins AS; Ordoñez JL; García-Sánchez A; Herrero D; Sevillano V; Osuna D; Mackintosh C; Caballero G; Otero AP; Poremba C; Madoz-Gúrpide J; de Alava E
    Cancer Res; 2008 Aug; 68(15):6260-70. PubMed ID: 18676850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel agents on the horizon for cancer therapy.
    Ma WW; Adjei AA
    CA Cancer J Clin; 2009; 59(2):111-37. PubMed ID: 19278961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
    Sangha R; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule inhibitors in children with malignant gliomas.
    Herrington B; Kieran MW
    Pediatr Blood Cancer; 2009 Sep; 53(3):312-7. PubMed ID: 19434732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.